Trichomoniasis

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

Global IVD Quality Control Industry Report 2023-2030: Third-Party Quality Controls in High Demand, Fueling Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 17, 2024
Health, Biotechnology, Conditional sentence, Hepatitis, Hospital, IVD, Syphilis, Gonorrhea, Infection, WHO, Quality control, Vertically transmitted infection, Fungal infection, STI, Birth, POC, Trichomoniasis, Diagnosis, Prevalence, Growth, Pharmaceutical industry

The "IVD Quality Control Market by Offering, Application, and End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "IVD Quality Control Market by Offering, Application, and End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The IVD quality control market is expected to reach $2.19 billion by 2030, at a CAGR of 4.3% from 2023 to 2030.
  • Among the offering, in 2023, the quality control products segment is estimated to account for the largest share of the IVD quality control market.
  • Among the application, in 2023, the infectious diseases segment is estimated to account for the largest share of the IVD quality control market.

Kesin Pharma Announces FDA Approval and U.S. Availability of LIKMEZ™ (metronidazole) Oral Suspension

Retrieved on: 
Tuesday, November 14, 2023
FDA, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, NDA, Vomiting, Metronidazole, Food, Argyreia nervosa, Amoebiasis, Infection, Headache, Tablet, Trichomoniasis, Constipation, Mouse, Patient, Refrigeration, Dysphagia, Prescription, Chronic pain, Diarrhea, Nausea, Partnership, Medicine, Rat, Taste, Pharmacy, Pharmaceutical industry

Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose formulations, announced today that the U.S. Food and Drug Administration (FDA) has approved LIKMEZ™ (metronidazole) oral suspension, 500 mg/5 mL.

Key Points: 
  • Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose formulations, announced today that the U.S. Food and Drug Administration (FDA) has approved LIKMEZ™ (metronidazole) oral suspension, 500 mg/5 mL.
  • Available now, LIKMEZ™ is the first and only FDA-approved ready-to-use oral liquid metronidazole in the U.S. market.
  • Kesin is the exclusive U.S. commercialization partner for LIKMEZ™ through its collaboration with Saptalis Pharmaceuticals, LLC, the developer and NDA holder of the product.
  • The timely approval of this NDA505(b)(2) presents a significant opportunity for Kesin Pharma to bring a value-added product to the market,” said Narasimhan Mani.

PHASE Scientific Americas Announces INDICAID Health™ At-Home Test Kits and Digital Health Platform

Retrieved on: 
Wednesday, October 25, 2023
Seniors, General Health, Health, Medical Devices, Convenience Store, Online Retail, Consumer, Retail, Science, Korea Disease Control and Prevention Agency, Chlamydia, CDC, STI, Gonorrhea, Vaginitis, COVID-19, Bacterial vaginosis, Pharmacy, Patient, Empathy, BV, Infection, Medical device, Trichomoniasis, COVID, Candidiasis

PHASE Scientific Americas (PHASE Scientific), a fast-growing, global biomedical company developing innovative solutions to revolutionize healthcare diagnostics, announces INDICAID health™, its new line of at-home health tests and digital health experiences.

Key Points: 
  • PHASE Scientific Americas (PHASE Scientific), a fast-growing, global biomedical company developing innovative solutions to revolutionize healthcare diagnostics, announces INDICAID health™, its new line of at-home health tests and digital health experiences.
  • INDICAID health™ was created to help patients get back to better health faster and with less hassle.
  • “INDICAID health™ supports PHASE Scientific’s mission of shaping the future of at-home, personal diagnostics with people-first, science-based innovations,” said Felix Chao, General Manager of PHASE Scientific Americas.
  • The INDICAID health™ Sexual Health 2 test checks for the top two common STIs: Chlamydia and Gonorrhea.

Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A

Retrieved on: 
Wednesday, September 27, 2023
Professional Services, Oncology, Start-Up, Consumer, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Baby, Maternity, Women, Biotechnology, Health, Pregnancy, Female, STI, Infection, Trichomoniasis, Gonorrhea, Discovery, Woman, Infertility, Prescription, Biomarker, Fungus, IRB, Data, Patient, Stanford University Medical Center, Preterm birth, Oncology nursing, Fertility, Chlamydia, Growth, Metagenomics, Bacteria, Research, Recurrence, System, PCR, Birth control, Nursing, Virtue

Vaginal discomfort is a leading reason that women seek healthcare advice in the US, with incredibly high misdiagnosis (>50%) and recurrence (>50%) rates.

Key Points: 
  • Vaginal discomfort is a leading reason that women seek healthcare advice in the US, with incredibly high misdiagnosis (>50%) and recurrence (>50%) rates.
  • Research has also uncovered groundbreaking links between the vaginal microbiome and infertility, STIs, preterm birth, gynecologic cancers, and more.
  • The Evvy Vaginal Health Test leverages mNGS to screen for all bacteria and fungi that have been isolated from the vaginal and urinary tract in a single swab.
  • They launched an integrative, personalized, AI-powered vaginal healthcare platform, and ran an IRB-approved study clinically validating that the platform improves the vaginal microbiome.

STIs are on the rise – here's how to navigate telling a partner if you've got one

Retrieved on: 
Tuesday, July 25, 2023
Vaccine, Infection, Contact tracing, Pregnancy, Life, HIV, STI, Friends, Education, Method, Public, Policy, Disclosure, Trichomoniasis, Taboo, World, Woman, Infertility, Guilt, Research, GP, COVID, Life expectancy, Language, Partner (business rank), Embarrassment, Gonorrhea, Shame, Man, Human, Risk, Cancer, Use-centered design, Quarterlife, Miscarriage, Stillbirth, Chlamydia, Diagnosis, Condom, NHS, Health, Mental health, Family, News, Syphilis, World Health Organization, Disease, Pharmaceutical industry, Birth control, Nursing, Online shopping

The number of gonorrhoea diagnoses recorded in England was in fact the highest since annual records began.

Key Points: 
  • The number of gonorrhoea diagnoses recorded in England was in fact the highest since annual records began.
  • On one hand you are being honest, responsible and respectful to your partner (or partners), and protecting their health.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
  • Letting sexual partners know if you have an STI is essential to the prevention, treatment and control of these infections.

Honesty is the best policy

    • For example, a single course of antibiotics will often clear chlamydia, gonorrhoea, syphilis and “trich” (trichomoniasis).
    • It’s totally normal to be anxious about your partner’s response and the potential effect on your relationship, whether casual or long term.
    • It’s also important to disclose if you have an STI before starting a sexual relationship with someone new.

What if a partner discloses that they have an STI?

    • When asking these questions, try to be mindful of the language you use, and avoid placing blame.
    • An early STI diagnosis is the best opportunity for effective treatment, and prevention of health complications and further transmission.
    • If you do decide to have sex, it’s advisable to use a physical barrier such as a condom or dental dam to protect your partner.

Make this an opportunity

    • Whether it’s you or your partner who have an STI – or both – use this opportunity to do some research on sexual health.
    • The COVID pandemic has also shown us the crucial role of early detection, rapid testing, and importantly, public health communication and education.
    • Overcoming STI stigma, much like COVID stigma, requires education, improving access to STI testing and treatment, and the promotion of inclusive conversations about sexual health.

Marty Zaluski, DVM, Joins GlobalVetLink as Head of Regulatory Affairs

Retrieved on: 
Monday, July 17, 2023
EHM, Veterinarian, Head, Trichomoniasis, GVL, Movement, Animal, Michigan State University College of Veterinary Medicine, Regulatory affairs, Health, Veterinary medicine, Brucellosis, Anthrax, DVM, Montana Department of Environmental Quality, AMES, Medical device

AMES, Iowa, July 17, 2023 /PRNewswire/ -- GlobalVetLink, the pioneer and leader in digital animal health and movement compliance, has announced the appointment of Martin Zaluski, DVM, as Head of Regulatory Affairs. With an extensive background in animal health, Dr. Zaluski brings a wealth of experience and expertise at the state and federal regulatory level to GlobalVetLink as the company continues to expand its role in automating complex regulatory compliance tasks for veterinarians. 

Key Points: 
  • Dr. Marty Zaluski has joined the animal health and movement compliance software company GlobalVetLink, where he will manage industry relations and platform compliance.
  • AMES, Iowa, July 17, 2023 /PRNewswire/ -- GlobalVetLink, the pioneer and leader in digital animal health and movement compliance, has announced the appointment of Martin Zaluski, DVM, as Head of Regulatory Affairs.
  • With an extensive background in animal health, Dr. Zaluski brings a wealth of experience and expertise at the state and federal regulatory level to GlobalVetLink as the company continues to expand its role in automating complex regulatory compliance tasks for veterinarians.
  • "I am excited to bring my experience in private and regulatory medicine, and passion for innovation to the GlobalVetLink team," said Dr. Martin Zaluski.

Simple HealthKit Launches At-Home Testing Kits on Walmart.com

Retrieved on: 
Monday, June 12, 2023
Gonorrhea, Type 2 diabetes, Wellness, Pharmacy, RI, Walmart, Quality of life, Health (Apple), Chlamydia, USPS, RSV, Trichomoniasis, Health, Diabetes, Glycated hemoglobin, Medical device

Simple HealthKit’s HbA1c (Diabetes) Tests identify key markers for Type 2 diabetes.

Key Points: 
  • Simple HealthKit’s HbA1c (Diabetes) Tests identify key markers for Type 2 diabetes.
  • “Early detection of health conditions can change an individual’s course and quality of life,” said Dr. Sheena Menezes, co-founder and CEO of Simple HealthKit.
  • Customers order the test with physician oversight, perform the test collection at home and send their sample via USPS to a Simple HealthKit lab.
  • “Simple HealthKit helps the patient bridge the gap between the test result and follow-up care.”
    In addition to working with retailers such as Walmart, Simple HealthKit works with pharmacies, educational institutions, employers and public health organizations to expand access to diagnostics in underserved communities.

To Counter Rapidly Rising STI Rates in the U.S., Simple HealthKit Launches At-Home Test For 5 Common STIs, Including Syphilis & HIV

Retrieved on: 
Thursday, May 25, 2023
Gonorrhea, Diabetes, STI, HIV, Aftercare, Health equity, Woman, Infertility, Innovation, Simple, Privacy, Health (Apple), CDC, Chlamydia, Trichomoniasis, PID, FSA, Health, Medical device, Birth control

The test is simple to use, easily available, inclusive and affordable, and includes a telehealth visit and aftercare for those who test positive for one or more conditions.

Key Points: 
  • The test is simple to use, easily available, inclusive and affordable, and includes a telehealth visit and aftercare for those who test positive for one or more conditions.
  • Tests are processed at Simple HealthKit’s CLIA-certified labs within 24 hours of receipt.
  • Syphilis rates in particular surged, increasing nearly 32 percent according to the CDC.
  • Simple HealthKit makes it easy and affordable to test for common conditions such as STIs, respiratory conditions, and diabetes.

binx health and the Elton John AIDS Foundation Aim to Break Down Barriers to PrEP and STI Screening Through Convenient binx everywhere At-home Solutions

Retrieved on: 
Tuesday, March 7, 2023
Organization, STI, Elton John AIDS Foundation, Chlamydia, Pre-exposure prophylaxis, Hepatitis B, Elton, Trichomoniasis, Geography, Gonorrhea, HIV, Hepatitis C, HIV/AIDS, HPV, Creatinine, Syphilis, Insurance, Infection, Pharmaceutical industry

“The Elton John AIDS Foundation and binx health have a shared commitment to make HIV testing and PrEP more accessible for those in greatest need,” said Anne Aslett, CEO of the Elton John AIDS Foundation.

Key Points: 
  • “The Elton John AIDS Foundation and binx health have a shared commitment to make HIV testing and PrEP more accessible for those in greatest need,” said Anne Aslett, CEO of the Elton John AIDS Foundation.
  • With binx health and the Elton John AIDS Foundation, now at-risk communities can receive care remotely and confidentially in a space of their choosing, without traveling to a clinic, and pick up their PrEP therapy where they wish, including binx partner pharmacies.
  • “We are especially proud to be supporting as esteemed an organization as the Elton John AIDS Foundation and look forward to working closely to help efforts in the battle against HIV/AIDS nationally.
  • Please visit ejaf.mybinxhealth.com to purchase individual kits or contact [email protected] for more information on bulk kits.